Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers

Item
http://www.wikidata.org/entity/Q26851202
First line vs delayed transplantation in myeloma: Certainties and controversiesOptimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.Distress and unmet needs during treatment and quality of life in early cancer survivorship: a longitudinal study of haematological cancer patients.The role of tandem stem cell transplantation for multiple myeloma patients.Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Developments in the Field of Myeloma in the Last Decade.The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.Is long term storage of cryopreserved stem cells for hematopoietic stem cell transplantation a worthwhile exercise in developing countries?Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.The evolution of stem-cell transplantation in multiple myeloma.Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
P2860

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers

Item
http://www.wikidata.org/entity/Q26851202
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Treatment of autologous stem c ...... nts: ten questions and answers
@ast
Treatment of autologous stem c ...... nts: ten questions and answers
@en
Treatment of autologous stem c ...... nts: ten questions and answers
@nl
type
label
Treatment of autologous stem c ...... nts: ten questions and answers
@ast
Treatment of autologous stem c ...... nts: ten questions and answers
@en
Treatment of autologous stem c ...... nts: ten questions and answers
@nl
prefLabel
Treatment of autologous stem c ...... nts: ten questions and answers
@ast
Treatment of autologous stem c ...... nts: ten questions and answers
@en
Treatment of autologous stem c ...... nts: ten questions and answers
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P577
P5875
P698
P932
P3181
P356
P1433
P1476
Treatment of autologous stem c ...... nts: ten questions and answers
@en
P2093
P2860
P304
P31
P3181
P356
10.3324/HAEMATOL.2013.096149
P407
P433
P478
P577
P5875
P698
P932